Active principle for cancer medication MGN1703 proven

MOLOGEN AG has taken a significant step forward in the development of its cancer medication. A further evaluation sequence of data from the company’s clinical study shows by means of biomarkers the potential of the active ingredient in the therapy of cancer.

MOLOGEN AG has evaluated a further sequence of clinical data from the completed phase Ib trial with the cancer medication MGN1703. The analysis of biomarkers of the patients’ immune system exemplarily shows the effect of MGN1703 on the immune system of cancer patients. It was shown that the immune system of the patients is broadly activated and in a manner that is necessary for a successful battle with tumor diseases.

The exemplary data achieved from the clinical trial confirms the results shown in preclinical trials and in vitro studies.

Prof. Dr. Burghardt Wittig, Chairman of the scientific advisory board of MOLOGEN AG, has commented: ”The evidence of activation markers for all cellular check points of the immune system can now be shown for the first time in patients with heavily damaged immune systems. The scientific concept of dSLIM®, the molecule which is behind MGN1703, has been confirmed by this once again.”

The data was seen as very positive, in light of the health condition of the patients who were being treated in the already completed clinical study of phase Ib. The immune system of the patients had been severely damaged from several month-long pretreatments with various types of chemotherapy, and as such, a successful evaluation of the biomarkers can not be assumed per se.

Dr. Matthias Schroff, CEO of MOLOGEN AG, has responded very optimistically to these interim results: "We have additional data on hand which proves the comprehensive effect of MGN1703 on the immune system. My confidence - especially as a scientist - is greater than ever that our current Phase II/III study will show the efficacy of the medication. We have been able to establish a link in the chain of evidence with this which should be meaningful not only for our entire product pipeline, but also for investors."

The cancer medication MGN1703 is currently being investigated in the course of a phase II/III clinical study that is relevant for the approval in the treatment of metastasized colorectal cancer. The goal of the study is to significantly prevent the progression of the cancer significantly longer than has been possible with the treatment methods up to now. The study is currently being conducted at various study centers in Germany and Austria. First results shall be available after an interim evaluation in the first half of 2011

More: www.mologen.com/data/News/EN_Mitteilungen/2010/100930.shtml

The MOLOGEN AG, a German biopharmaceutical company with headquarters in Berlin specializes in the research and development of innovative medications on the basis of DNA structures. The activities focus on numerous product developments which are relevant to the immune system; on the one hand vaccines against infectious diseases and on the other hand cancer medications. MOLOGEN AG is globally one of the few biotechnology companies with well tolerated DNA-based cancer treatment in the clinical development phase.

The stocks of MOLOGEN AG are listed in the Prime Standard of the German stock exchange. (ISIN DE0006637200).

Memberships in associations:
BIO Deutschland e.V. | DECHEMA - Society for chemical technology and biotechnology e.V. | German industrial association of biotechnology (DIB) | Association for the Promotion of Science and Humanities in Germany | Association of German biotechnology companies (VBU) | Association of researching manufacturers of pharmaceuticals e.V. (VFA) | Association of the chemical industry e.V. (VCI)

MIDGE®, dSLIM ® and MOLOGEN ® are registered trademarks of MOLOGEN AG.

Note about risk for future predictions
Certain information in this report contains forward-looking statements or the corresponding statements with negation or versions deviating from this or comparable terminology. These are described as forward-looking statements. In addition, all of the information given here that refers to planned or future results of business areas, key financial figures, developments of the financial situation or other financial figures or statistical data, is to be understood as such forward-looking statements. The company points out to investors that they should not rely on these forward-looking statements as predictions about actual future events. The company is not obligated and refuses to accept any liability for the forward-looking statements and has no obligation to update such statements in order to accurately reflect the current situation.

MOLOGEN AG
Department for Corporate Communiations
Fabeckstr. 30
D-14195 Berlin

Contact:
Prof. Peter W. Hübner
Head of Corporate Communications

T. +49 - 30 - 84 17 88 - 38
F. +49 - 30 - 84 17 88 - 50
www.mologen.com

This release was published on openPR.